Interestingly, SpA, RA, and IBD share clinical responsiveness to anti-tumor necrosis factor (TNF)-α therapy but significantly differ in their response toward inhibition of other key inflammatory cytokines like IL-17. This evidence concerns the gene IL17A and rheumatoid arthritis.